Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial
Authors:
- 1 March 2016
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 173, 134-142
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trialEuropean Heart Journal, 2011
- A Prospective Natural-History Study of Coronary AtherosclerosisNew England Journal of Medicine, 2011
- Type 3 Phosphodiesterase Inhibitors May Be Protective Against Cerebrovascular Events in Patients with ClaudicationJournal of Stroke and Cerebrovascular Diseases, 2008
- Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular EventsThe American Journal of Cardiology, 2008
- Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects)Journal of Vascular Surgery, 2008
- Comparison of Triple Versus Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation (from the DECLARE–Long Trial)The American Journal of Cardiology, 2007
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Low-Dose Aspirin for the Prevention of AtherothrombosisNew England Journal of Medicine, 2005
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingNew England Journal of Medicine, 1998